계명대학교 의학도서관 Repository

Carfilzomib in addition to lenalidomide and dexamethasone in Asian patients with RRMM outside of a clinical trial

Metadata Downloads
Author(s)
Ji Hyun LeeYong ParkKa-Won KangJe-Jung LeeHo Sup LeeHyeon-Seok EomYoung Rok DoJin Seok KimSung-Soo YoonDong-Yeop ShinYoungil KohKi-Hyun KimWon Sik LeeJae-Cheol JoYoo Jin LeeJi Yun LeeDae Sik KimHyeok ShimMyung Hee ChangSung-Hyun KimChang-Ki Min
Keimyung Author(s)
Do, Young Rok
Department
Dept. of Internal Medicine (내과학)
Journal Title
Ann Hematol
Issued Date
2021
Volume
100
Issue
8
Keyword
CarfilzomibLenalidomideRelapsed and refractorymultiplemyelomaReal-worldAsia
Abstract
Carfilzomib, lenalidomide, and dexamethasone (KRd) effectively improve survival in patients with relapsed and refractory multiple myeloma (RRMM). However, the outcome of KRd treatment in Asian patients reflecting a general RRMM population outside of a clinical trial has not been reported. Fifty-five RRMM patients who were treated with carfilzomib in combination with Rd from the time of the first approval of KRd in the Republic of Korea were analyzed. The median age was 61 years. The percentage of patients with an ECOG performance status ≥ 3, creatinine clearance < 50 mL/min, high-risk cytogenetics, and ≥ 4 lines of prior treatment were 9%, 22%, 31%, and 27%, respectively. Forty-one patients started treatment with KRd, whereas the remaining 14 patients (25%) were added carfilzomib during the Rd treatment. In the whole cohort, the overall response rate was 73% and progression-free survival was 8.8 months. The addition of carfilzomib in patients who were refractory or had disease progression during Rd treatment reattained a response in half of the patients. The advantage of carfilzomib with Rd was significant in patients in the first relapse. Toxicity profile was acceptable, excluding severe infections. Carfilzomib in combination with Rd is effective and has a reasonable adverse event rate in Asian patients with RRMM.
Keimyung Author(s)(Kor)
도영록
Publisher
School of Medicine (의과대학)
Citation
Ji Hyun Lee et al. (2021). Carfilzomib in addition to lenalidomide and dexamethasone in Asian patients with RRMM outside of a clinical trial. Ann Hematol, 100(8), 2051–2059. doi: 10.1007/s00277-021-04407-0
Type
Article
ISSN
1432-0584
Source
https://link.springer.com/article/10.1007%2Fs00277-021-04407-0
DOI
10.1007/s00277-021-04407-0
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/43567
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
  • 엠바고Forever
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.